Table 2.
Characteristics of 1,468 Patients Receiving Bedaquiline for at Least 24 Weeks, endTB (Expand New Drug Markets for TB) Cohort, 2015–2018
| Characteristic | n (%)* | Missing [n (%)] |
|---|---|---|
| Assessed at treatment initiation | ||
| Age at treatment initiation, yr, median (IQR; range) | 34 (26–45; 10–78) | — |
| Female sex | 531 (36.2) | — |
| HIV infection | 95 (6.5) | 1 (0.1) |
| Hepatitis C | 139 (9.5) | 3 (0.2) |
| Previous TB treatment with second-line drugs | 1,181 (80.5) | — |
| Resistance profile | ||
| RR/MDR-TB with FQ and injectable both sensitive | 203 (13.8) | — |
| RR/MDR-TB without testing to FQ and injectable | 77 (5.2) | — |
| RR/MDR-TB with injectable resistance, FQ sensitive | 182 (12.4) | — |
| RR/MDR-TB with FQ resistance, injectable sensitive | 402 (27.4) | — |
| RR/MDR-TB with FQ and injectable both resistant | 554 (37.7) | — |
| Not tested for RR/MDR-TB | 30 (2.0) | — |
| Assessed at 23 wk | ||
| Complete data on adherence | 1,294 (88.2) | — |
| Adherence rate > 80% among those with complete adherence (n = 1,294) | 1,163 (89.9) | — |
| Positive sputum culture | 78 (5.3) | 13 (0.9) |
| Extensive disease | — | 149 (10.1) |
| No cavitary disease, no smear 3+ | 460 (31.3) | — |
| Cavitary disease, smear <3+ | 845 (57.6) | — |
| No cavitary disease, smear 3+ | 4 (0.3) | — |
| Cavitary disease, smear 3+ | 10 (0.7) | — |
| BMI < 18.5 kg/m2 | 448 (30.5) | 7 (0.5) |
| Functional status | — | 124 (8.4) |
| Fully active | 726 (49.5) | — |
| Ambulatory | 468 (31.9) | — |
| Capable of self-care | 112 (7.6) | — |
| Limited self-care | 27 (1.8) | — |
| Completely disabled | 11 (0.7) | — |
| FQ | 724 (49.3) | — |
| Likely effective† | 494 (33.7) | — |
| Linezolid | 1,323 (90.1) | — |
| Likely effective | 1,278 (87.1) | — |
| Clofazimine | 1,209 (82.4) | — |
| Likely effective | 1,140 (77.7) | — |
| Cycloserine | 831 (56.6) | — |
| Likely effective | 266 (18.1) | — |
| Delamanid | 311 (21.2) | — |
| Likely effective | 309 (21.1) | — |
| Number of likely effective drugs, median (IQR; range) | 4 (4–5; 1–9) | — |
Definition of abbreviations: BMI = body mass index; FQ = fluoroquinolone; IQR = interquartile range; MDR = multidrug-resistant; RR = rifampicin-resistant; TB = tuberculosis.
*
Unless otherwise noted.
†
A drug was considered likely effective if 1) all reported testing (phenotypic or genotypic) of that drug confirmed susceptibility or 2) no resistance to the drug was reported and the patient had not previously received the drug for 1 month or more. Otherwise, the drug was not considered likely effective.